MALIGNANT PLEURAL MESOTHELIOMA
Clinical trials for MALIGNANT PLEURAL MESOTHELIOMA explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT PLEURAL MESOTHELIOMA trials appear
Sign up with your email to follow new studies for MALIGNANT PLEURAL MESOTHELIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Light therapy boosts immune attack on lung cancer? early trial halted
Disease control TerminatedThis early-phase trial tested whether a light-activated drug (photodynamic therapy) could help immunotherapy work better in patients with non-small cell lung cancer that has spread to the lining of the lung or with mesothelioma. Only 5 people took part, and the study was stopped …
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Immunotherapy combo studied for rare lung cancer, trial stopped early
Disease control TerminatedThis study tested two immunotherapy drugs, durvalumab and tremelimumab, in people with malignant pleural mesothelioma, a rare cancer of the lung lining. The trial enrolled 19 participants whose cancer had worsened after standard chemotherapy. The goal was to see if the drug combi…
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental lung cancer combo trial ends early
Disease control TerminatedThis phase 2 trial tested a new drug called THOR-707 (Pegenzileukin) combined with other cancer treatments, including pembrolizumab, in 106 people with advanced lung cancer or pleural mesothelioma. The goal was to see if the combination could shrink tumors. However, the study was…
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Mesothelioma drug trial halted early – what we know
Disease control TerminatedThis phase 2 trial tested whether the drug nintedanib could help people with malignant pleural mesothelioma keep their cancer from growing after initial chemotherapy. 37 patients were randomly assigned to receive either nintedanib or a placebo twice daily. The study was terminate…
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Phase: PHASE2 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 26, 2026 18:48 UTC